Essential role of RSK2 in c-Fos-dependent osteosarcoma development

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 664-672

  David, Jean Pierre ^a,c   Mehic, Denis ^a   Bakiri, Latifa ^a   Schilling, Arndt F ^b   Mandic, Vice ^c   Priemel, Matthias ^b   Idarraga, Maria Helena ^a   Reschke, Markus O ^a   Hoffmann, Oskar ^d   Amling, Michael ^b   Wagner, Erwin F ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b University of Medical School Hamburg Eppendorf   (Germany)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RSK2; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; COFFIN LOWRY SYNDROME; MENTAL DEFICIENCY; NONHUMAN; ONCOGENE C FOS; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; SKELETON MALFORMATION; X CHROMOSOME LINKED DISORDER;

ANIMALS; BONE AND BONES; BONE DISEASES, METABOLIC; CELL DIFFERENTIATION; CELLS, CULTURED; COFFIN-LOWRY SYNDROME; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCLASTS; OSTEOSARCOMA; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 20044390185     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200522877     Document Type: Article

References (42)

1. Karsenty, G., and Wagner, E.F. 2002. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2:389-406.
2. Jochum, W., Passegue, E., and Wagner, E.F. 2001. AP-1 in mouse development and tumorigenesis. Oncogene. 20:2401-2412.
3. Eferl, R., and Wagner, E.F. 2003. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer. 3:859-868.
4. Wang, Z.Q., et al. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature. 360:741-745.
5. Johnson, R.S., Spiegelman, B.M., and Papaioannou, V. 1992. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell. 71:577-586.
6. Grigoriadis, A.E., Schellander, K., Wang, Z.Q., and Wagner, E.F. 1993. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 122:685-701.
7. Pearman, A.T., Chou, W.Y., Bergman, K.D., Pulumati, M.R., and Partridge, N.C. 1996. Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J. Biol. Chem. 271:25715-25721.
8. McCauley, L.K., Koh, A.J., Beecher, C.A., and Rosol, T.J. 1997. Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology. 138:5427-5433.
9. Deng, T., and Karin, M. 1994. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature. 371:171-175.
10. Chen, R.H., Juo, P.C., Curran, T., and Blenis, J. 1996. Phosphorylation of c-Fos at rhe C-rerminus enhances its transforming activity. Oncogene. 12:1493-1502.
11. Okazaki, K., and Sagata, N. 1995. The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J. 14:5048-5059.
12. Murphy, L.O., Smith, S., Chen, R.H., Fingar, D.C., and Blenis, J. 2002. Molecular interpretation of ERK signal duration byimmediate early gene products. Nat. Cell Biol. 4:556-564.
13. Takayanagi, H., et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 416:744-749.
14. Nebreda, A.R., and Gavin, A.C. 1999. Perspectives: signal transduction. Cell survival demands some Rsk. Science. 286:1309-1310.
15. De Cesare, D., Jacquot, S., Hanauer, A., and Sassone-Corsi, P. 1998. Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. U. S. A. 95:12202-12207.
16. Bruning, J.C., et al. 2000. Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene. Proc. Natl. Acid. Sci. U. S. A. 97:2462-2467.
17. Cheung, P., et al. 2000. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol. Cell. 5:905-915.
18. Hanauer, A., and Young, I.D. 2002. Coffin-Lowry syndrome: clinical and molecular features. J. Med. Genet. 39:705-713.
19. Dufresne, S.D., et al. 2001. Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice. Mol. Cell. Biol. 21:81-87.
20. Yang, X., et al. 2004. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry Syndrome. Cell. 117:387-398.
21. Anonymous. 1995. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-Linked hypophosphatemic rickets. The HYP Consortium. Nat. Genet. 11:130-136.
22. Econs, M.J., et al. 1998. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 83:3459-3462.
23. Strom, T.M., et al. 1997. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum. Mol. Genet. 6:165-171.
24. Wang, Z.Q., Liang, J., Schellander, K., Wagner, E.F., and Grigoriadis, A.E. 1995. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55:6244-6251.
25. Vahle, J.L., et al. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol. 30:312-321.
26. Alessi, D.R. 1997. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase. FEBS Lett. 402:121-123.
27. Fleischmann, A., et al. 2003. Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J. Neurosci. 23:9116-9122.
28. Quarles, L.D. 2003. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeleral mineralization. Am. J. Physiol. Endocrinol. Metab. 285:E1-E9.
29. Miao, D., et al. 2001. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology. 142:926-939.
30. Meyer, R.A., Jr., Young, C.G., Meyer, M.H., Garges, P.L., and Price, D.K. 2000. Effect of age on the expression of Pex (Phex) in the mouse. Calcif. Tissue Int. 66:282-287.
31. Ruchon, A.F., et al. 2000. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J. Bone Miner. Res. 15:1440-1450.
32. Ruther, U., Komitowski, D., Schubert, F.R., and Wagner, E.F. 1989. c-fos expression induces bone tumors in transgenic mice. Oncogene. 4:861-865.
33. Papachristou, D.J., Batistatou, A., Sykiotis, G.P., Varakis, I., and Papavassiliou, A.G. 2003. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone. 32:364-371.
34. Grigoriadis, A.E., et al. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266:443-448.
35. Acquaviva, C., et al. 2001. Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos protooncoprotein during the G(0)-to-S phase transition. Oncogene. 20:7563-7572.
36. Ferrara, P., et al. 2003. The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene. 22:1461-1474.
37. Saez, E., et al. 1995. c-fos is required for malignant progression of skin tumors. Cell. 82:721-732.
38. Jochum, W., et al. 2000. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6:980-984.
39. David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H., and Wagner, E.F. 2002. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115:4317-4325.
40. Bakiri, L., Lallemand, D., Bossy-Wetzel, E., and Yaniv, M. 2000. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 19:2056-2068.
41. Amling, M., et al. 1999. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology. 140:4982-4987.
42. Parfitt, A.M., et al. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:595-610.